

Xiaomei Cai

Associate

Phoenix

T +1 602 528 4000

xiaomei.cai@squirepb.com

Languages spoken

Mandarin | English



About Xiaomei

Xiaomei Cai is an associate in the Intellectual Property & Technology practice, representing clients from a wide range of industries in intellectual property disputes, including Hatch-Waxman litigation, International Trade Commission (ITC) Section 337 proceedings, Wi-Fi technology, biologics litigation, chemistry and semiconductors, focusing on pharmaceutical and biotechnology.

Xiaomei's practice encompasses all facets of complex patent litigation, including pre-suit investigation and counseling, discovery, claim construction and *Markman* hearings, trials, post-trial, injunction proceedings and appeals, before federal courts. She also represents clients in regulatory proceedings such as *inter partes* reviews before the Property Tax Appeal Board (PTAB), as well as in cross-border enforcement actions such as ITC Section 337 investigations. Xiaomei combines scientific acumen with a keen understanding of the legal issues that surround bringing new technology products and innovative services to the market.

She also has substantial experience handling China-related intellectual property matters and cross-border IP disputes spanning chemical, pharmaceutical, biotechnology and consumer electronics. For example, Xiaomei has:

- Represented a leading Chinese polymer manufacturer in an ITC 337 investigation
- Represented a biopharmaceutical company in a patent infringement action against online retailers of bioactive and small molecules compounds into the US
- Defending a China-based manufacturer of HDMI products in cross-border litigation involving claim of trade secret misappropriation
- Defending a China-based manufacturer of espresso machine products in a litigation involving claim of trademark infringement
- Advised a leading Chinese food and flavoring company relating to the analysis of patent noninfringement of equipment and processes for soy source manufacturing
- counseled a Chinese pharmaceutical company relating to its defense against patent infringement claims in connection with its Abbreviated New Drug Application (ANDA) application

Credentials

Education

- Washington University School of Law, J.D., 2017
- Tianjin University (China), M.S., Pharmaceutical Sciences, 2014
- Tianjin University (China), B.S., Pharmaceutical Sciences, 2011

Admissions

- Arizona, 2023
- Illinois, 2017

Courts

- Court of Appeals for the Federal Circuit, 2020
- Illinois Northern District Court, 2017

Expertise

Services

- Intellectual Property & Technology

About our firm

One of the world's strongest integrated law firms, providing insight at the point where law, business and government meet. We deliver commercially focused business solutions by combining our legal, lobbying and political capabilities and invaluable connections on the ground to a diverse mix of clients, from long-established leading corporations to emerging businesses, startup visionaries and sovereign nations. More than 1,500 lawyers in over 40 offices across four continents provide unrivaled access to expertise.